Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Howard Reber, M.D.
Howard Reber, M.D.


Surgery General

General Information:



Distinguished Professor, Department of Surgery
Director, Department of Medicine, Hematology/Oncology, Pancreatic Cancer Program
Physician, General Surgery, Pancreatic Disease
Member, JCCC Community

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center


Surgery, Hospital of the University of Pennsylvania, 1964 - 1970
Rotating (Internship), Hospital of the University of Pennsylvania, 1963 - 1964
Medical Degree:
M.D., University of Pennsylvania School of Medicine, 1963


Board Certification(s):
Surgery, American Board of Surgery, 1971

Contact Information:

(310) 794-7788 Information, referral and outpatient clinic appointments - Westwood
(310) 319-4080 Information, referral and outpatient clinic appointments - Santa Monica
(310) 825-1597 Pancreatic Disease information and referral

Practice Information:

Clinical Interest(s):

Scientific Interest(s):

Dr. Howard Reber's research focuses on acute and chronic pancreatitis, as well as pancreatic cancer.

Selected Cancer-Related Publications:

Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg. 2008 Dec;143(12):1166-71.

Bhargava S, Hotz B, Hines OJ, Reber HA, Buhr HJ, Hotz HG. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg. 2007; 11:171-178.

Buchler P, Reber HA, Roth MM, Shiroishi M, Friess, Hines OJ. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia. 2007; 9:119-127.

Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007; 67:7068-7071.

Tomlinson JS, Jain S, Bentrem DJ, Sekeris EG, Maggard MA, Hines OJ, Reber HA, Ko CY. Accuracy of staging node negative pancreas cancer: a potential quality measure. Arch Surg. 2007; 142:767-774.